Novo Obesity Pill Faces Market Challenges
Novo Nordisk faces market share risks and supply capacity questions regarding its upcoming obesity pill. Eli Lilly launched a competing obesity pill last month, creating potential competition.
Topics
Developing
- 863d Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore.
- 863d Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
- 863d Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est.
- 863d Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium.
Sources · 7 independent
Bloomberg Radio
“Eli Lilly has just launched its own obesity pill just last month. So there is a risk of losing market share to this new drug. And there's also questions surrounding supply capacity when the pill from Novo actually launches in other countries beyond the US.”
Unlock the full story
Get a Pro subscription or above to see the live story progression and the full list of independent sources confirming each event as they happen.
Log in to upgrade